New research from the University of Aberdeen suggests weight loss medications could deliver a double benefit, improving people's health while also helping the environment.
Scientists from Aberdeen, in collaboration with the University of Edinburgh and Scotland’s Rural College (SRUC) investigated how widespread uptake of GLP-1 medications such as Ozempic and Mounjaro for obesity, could potentially affect global food demand, food prices, international trade, agricultural land use and mortality together. The study is published in Nature Communications.
In the team’s most ambitious scenarios, widespread GLP-1 use could be associated with up to 6.6 million fewer deaths globally in 2050 and around 32 million hectares more land outside agriculture and managed forestry. If treatment were accompanied by healthier diets, the potential benefits increased to 7.7 million fewer deaths and around 46 million hectares more land.
Dr Roslyn Henry from the University of Aberdeen led the study. She said: “Our findings suggest that these changes in food consumption could have consequences that extend beyond the individuals receiving treatment, including potentially reducing pressure on natural land in other parts of the world.
“However, it's important that these findings aren't interpreted as placing environmental responsibility on people living with obesity, or suggesting that medication is an environmental solution. The environmental impacts of what we eat are shaped by the wider food system, not simply by individual choices.
“Our results also highlight the importance of supporting healthier diets alongside treatment. This requires not only targeted guidance for GLP-1 users, but also wider policies that make healthy and sustainable diets more accessible and affordable for everyone.”
Professor Peter Alexander of the University of Edinburgh and co-author of the study, added: “What we eat has consequences that extend beyond our own health. Our food choices ripple through global food systems, affecting what farmers produce, what countries trade and how much land is needed for agriculture. As appetite-suppressing and other pharmaceutical treatments become more widely used, we need to understand how their uptake could reshape food systems, and the resulting environmental impacts and health outcomes.”
This research is a first exploratory assessment of the potential impact on the food-system of widespread uptake of GLP-1 medications, rather than forecasts of future treatment trajectories or a recommendation for universal treatment. Alternative assumptions regarding adherence, treatment duration, changes in dietary intake and weight regain could be explored in future work, particularly as treatment options and access to treatments evolve.